TELA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.77 USD | +16.80% |
|
+22.25% | -12.84% |
| May. 10 | Piper Sandler Adjusts Price Target on TELA Bio to $10 From $12, Maintains Overweight Rating | MT |
| May. 09 | Earnings Flash (TELA) TELA BIO Posts Q1 Revenue $16.6M, vs. Street Est of $16.3M | MT |
Evolution of the average Target Price on TELA Bio, Inc.
Price target over the last 5 years
History of analyst recommendation changes
2938.Y_J_Wc_YgbwCAc-xo1nkAXI4MNS50zSVjofAn0Cn1WI.U8EzL73v3sVxUYiA5wmANy1_UrD3kmPj3ffz0A3yhC1TqDARlqDG5nhs-w~914fd215586aadc951852e46e7457c66
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.77
USD
Average target price
14.2
USD
Spread / Average Target
+146.10%
High Price Target
18
USD
Spread / Highest target
+211.96%
Low Price Target
10
USD
Spread / Lowest Target
+73.31%
Consensus detail
Consensus revision (last 18 months)
Analysts covering TELA Bio, Inc.
| Piper Sandler | |
| JMP Securities |
Trading Rating
Investor Rating
ESG Refinitiv
C-
EPS Revisions
- Stock Market
- Equities
- TELA Stock
- Consensus TELA Bio, Inc.
